The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: A review
Open accessAbstract
Caffeine is the most consumed pychostimulant in the world, and it is known to affect basic and fundamental human processes such as sleep, arousal, cognition and learning and memory. It works as a nonselective blocker of adenosine receptors (A1, A2a, A2b and A3) and has been related to the regulation of heart rate, the contraction/relaxation of cardiac and smooth muscles, and the neural signaling in the central nervous system (CNS). Since the late 1990s, studies using adenosine receptor antagonists, such as Caffeine, to block the A1 and A2a adenosine receptor subtypes have shown to reduce the physical, cellular and molecular damages caused by a spinal cord injury (SCI) or a stroke (cerebral infarction) and by other neurodegenerative diseases such as Parkinson's and Alzheimer's diseases. Interestingly, other studies using adenosine receptor agonists have also shown to provide a neuroprotective effect on various models of neurodegenerative diseases through the reduction of excitatory neurotransmitter release, apoptosis and inflammatory responses, among others. The seemingly paradoxical use of both adenosine receptor agonists and antagonists as neuroprotective agents has been attributed to differences in dosage levels, drug delivery method, extracellular concentration of excitatory neurotransmitters and stage of disease progression. We discuss and compare recent findings using both antagonists and agonists of adenosine receptors in animal models and patients that have suffered spinal cord injuries, brain strokes, and Parkinson's and Alzheimer's diseases. Additionally, we propose alternative interpretations on the seemingly paradoxical use of these drugs as potential pharmacological tools to treat these various types of neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
An Update on the Mechanisms of the Psychostimulant Effects of Caffeine
Ferré, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05196.x · Cited by 440 · cited 5×
“Caffeine has been described to have the ability to influence dopaminergic neurotransmission and potentiate dopamine receptor-mediated behavioral responses, such as locomotion and cognitive functions (Ferré, 2008; Xie et al., 2007).”
BackgroundInfluentialTarkowski, E., Blennow, K., Wallin, A., & Tarkowski, A. (1999) · Journal of Clinical Immunology · doi:10.1023/a:1020568013953 · Cited by 349
Arendash, G. W., Mori, T., Cao, C., Mamcarz, M., Runfeldt, M., Dickson, A., Rezai-Zadeh, K., Tan, J., Citron, B. A., Lin, X., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1087 · Cited by 308
Effects of caffeine on sleep and cognition
Snel, J., & Lorist, M. M. (2011) · Progress in brain research · doi:10.1016/b978-0-444-53817-8.00006-2 · Cited by 187 · cited 1×
“Conclusions Recent experimental evidence suggests that the primary target for the neuroprotective effects of caffeine (Glade, 2010; Snel and Lorist, 2011), the most consumed psychostimulant in the world (Nehlig et al., 1992), is mostly through either the activation or inhibition of the A1 and A2a…”
BackgroundCaffeine and risk of Parkinson’s disease in a large cohort of men and women
Palacios, N., Gao, X., McCullough, M. L., Schwarzschild, M. A., Shah, R., Gapstur, S., & Ascherio, A. (2012) · Movement Disorders · doi:10.1002/mds.25076 · Cited by 185
Bermejo, P., Martín-Aragón, S., Benedí, J., Susín, C., Felici, E., Gil, P., Ribera, J. M., & Villar, Á. M. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.02.002 · Cited by 178
Coffee Intake in Midlife and Risk of Dementia and its Neuropathologic Correlates
Gelber, R. P., Petrovitch, H., Masaki, K. H., Ross, G. W., & White, L. R. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101428 · Cited by 133
Coffee and acute ischemic stroke onset: The Stroke Onset Study
Mostofsky, E., Schlaug, G., Mukamal, K. J., Rosamond, W. D., & Mittleman, M. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fb443d · Cited by 75
Cited by
Spinal Cord Injury: Pathophysiology, Multimolecular Interactions, and Underlying Recovery Mechanisms
Anjum, A., Yazid, M. D., Fauzi Daud, M., Idris, J., Ng, A. M. H., Selvi Naicker, A., Ismail, O. H. R., Athi Kumar, R. K., & Lokanathan, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207533 · Cited by 1,270
The biphasic function of microglia in ischemic stroke
Ma, Y., Wang, J., Wang, Y., & Yang, G.-Y. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.005 · Cited by 655
Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders
Hussain, G., Rasul, A., Anwar, H., Aziz, N., Razzaq, A., Wei, W., Ali, M., Li, J., & Li, X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23247 · Cited by 351
Medicinal chemistry of adenosine, P2Y and P2X receptors
Jacobson, K. A., & Müller, C. E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.001 · Cited by 262
Zeng, J., Bao, T., Yang, K., Zhu, X., Wang, S., Xiang, W., Ge, A., Zeng, L., & Ge, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1047550 · Cited by 175
Metadata
- Authors
- Rivera-Oliver, M., & Díaz-Ríos, M.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 101
- Issue
- 1-2
- Pages
- 1-9
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W2089043139
- Cited by
- 202
- References
- 9
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.